{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:51:38Z","timestamp":1777503098265,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","nanomedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.nano.2015.11.007","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T07:50:06Z","timestamp":1449215406000},"page":"759-770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin"],"prefix":"10.1016","volume":"12","author":[{"given":"Yu-Na","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Suk","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Eun-Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-331X","authenticated-orcid":false,"given":"Sang-Moo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2015.11.007_bb0005","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2015.11.007_bb0010","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.nano.2015.11.007_bb0015","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","article-title":"Respiratory syncytial virus and recurrent wheeze in healthy preterm infants","volume":"368","author":"Blanken","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2015.11.007_bb0020","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.nano.2015.11.007_bb0025","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1128\/JVI.01625-07","article-title":"Viral and host factors in human respiratory syncytial virus pathogenesis","volume":"82","author":"Collins","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development","volume":"239","author":"Graham","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.nano.2015.11.007_bb0035","first-page":"391","article-title":"Challenges and opportunities for respiratory syncytial virus vaccines","volume":"372","author":"Graham","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.nano.2015.11.007_bb0040","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1097\/01.inf.0000053885.34703.84","article-title":"Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage","volume":"22","author":"Romero","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.nano.2015.11.007_bb0045","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.nano.2015.11.007_bb0050","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","article-title":"Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract","volume":"368","author":"Wu","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1016\/j.nano.2015.11.007_bb0055","first-page":"CD006602","article-title":"Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children","volume":"4","author":"Andabaka","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nano.2015.11.007_bb0060","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1073\/pnas.100133697","article-title":"A DNA transfection system for generation of influenza A virus from eight plasmids","volume":"97","author":"Hoffmann","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2015.11.007_bb0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/biol.1995.0028","article-title":"Influenza virus vectors","volume":"23","author":"Garcia-Sastre","year":"1995","journal-title":"Biologicals"},{"key":"10.1016\/j.nano.2015.11.007_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.12.009","article-title":"Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease","volume":"115","author":"Lee","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.nano.2015.11.007_bb0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.virol.2014.12.004","article-title":"Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease","volume":"476","author":"Lee","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.nano.2015.11.007_bb0080","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1128\/JVI.67.11.6659-6666.1993","article-title":"Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1","volume":"67","author":"Li","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0085","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1128\/JVI.66.1.399-404.1992","article-title":"Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes","volume":"66","author":"Li","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0090","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1016\/S0264-410X(02)00268-2","article-title":"Eight-plasmid system for rapid generation of influenza virus vaccines","volume":"20","author":"Hoffmann","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2015.11.007_bb0095","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1099\/0022-1317-82-12-2881","article-title":"Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine","volume":"82","author":"Prince","year":"2001","journal-title":"J Gen Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0100","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1016\/j.vaccine.2014.08.045","article-title":"Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus","volume":"32","author":"Lee","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2015.11.007_bb0105","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1128\/JVI.62.11.4232-4238.1988","article-title":"Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies","volume":"62","author":"Anderson","year":"1988","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.nano.2014.07.013","article-title":"Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells","volume":"11","author":"Ko","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2015.11.007_bb0115","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/0192623308329342","article-title":"Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model","volume":"37","author":"Meyerholz","year":"2009","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.nano.2015.11.007_bb0120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2014.07.016","article-title":"Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis","volume":"110","author":"Hwang","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.nano.2015.11.007_bb0125","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1128\/JVI.01709-09","article-title":"Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB\/c mice, with no evidence of immunopathology","volume":"84","author":"Murawski","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0130","doi-asserted-by":"crossref","first-page":"13710","DOI":"10.1128\/JVI.01351-07","article-title":"Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats","volume":"81","author":"Mok","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0135","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0092-8674(82)90135-0","article-title":"The antigenic structure of the influenza virus A\/PR\/8\/34 hemagglutinin (H1 subtype)","volume":"31","author":"Caton","year":"1982","journal-title":"Cell"},{"key":"10.1016\/j.nano.2015.11.007_bb0140","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/289373a0","article-title":"Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation","volume":"289","author":"Wiley","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.nano.2015.11.007_bb0145","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1128\/JVI.00555-11","article-title":"Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes","volume":"85","author":"McLellan","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0150","doi-asserted-by":"crossref","first-page":"6971","DOI":"10.1016\/j.vaccine.2012.09.059","article-title":"Adjuvants and inactivated polio vaccine: a systematic review","volume":"30","author":"Hawken","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2015.11.007_bb0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.nano.2015.11.007_bb0160","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1084\/jem.182.4.1169","article-title":"Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo","volume":"182","author":"Collins","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.nano.2015.11.007_bb0165","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.4049\/jimmunol.180.4.2376","article-title":"IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease","volume":"180","author":"Castilow","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.nano.2015.11.007_bb0170","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1189\/jlb.0907621","article-title":"Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein","volume":"84","author":"Johnson","year":"2008","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.nano.2015.11.007_bb0175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jim.2003.09.001","article-title":"Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells","volume":"283","author":"Karlsson","year":"2003","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.nano.2015.11.007_bb0185","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/oxfordjournals.aje.a120957","article-title":"Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population","volume":"89","author":"Chin","year":"1969","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.nano.2015.11.007_bb0195","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1542\/peds.105.1.79","article-title":"Eosinophilia at the time of respiratory syncytial virus bronchiolitis predicts childhood reactive airway disease","volume":"105","author":"Ehlenfield","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.nano.2015.11.007_bb0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/jcp.23.1.7","article-title":"Pathological changes in virus infections of the lower respiratory tract in children","volume":"23","author":"Aherne","year":"1970","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.nano.2015.11.007_bb0205","first-page":"95","article-title":"Pathogenesis and treatment of bronchiolitis","volume":"12","author":"Lugo","year":"1993","journal-title":"Clin Pharm"},{"key":"10.1016\/j.nano.2015.11.007_bb0210","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1128\/JVI.03019-12","article-title":"Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice","volume":"87","author":"De Baets","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0215","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1128\/JVI.68.7.4486-4492.1994","article-title":"Expression of a foreign protein by influenza A virus","volume":"68","author":"Percy","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0220","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2014.01.022","article-title":"Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB\/c mice","volume":"104","author":"Bian","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.nano.2015.11.007_bb0225","doi-asserted-by":"crossref","first-page":"8899","DOI":"10.1128\/JVI.75.19.8899-8908.2001","article-title":"Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice","volume":"75","author":"Ferko","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0230","first-page":"1067","article-title":"A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus","volume":"195","author":"Fonseca","year":"2013","journal-title":"Arch Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0235","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1128\/JVI.06232-11","article-title":"A replication-incompetent PB2-knockout influenza A virus vaccine vector","volume":"86","author":"Victor","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0240","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/infdis\/jir661","article-title":"Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection","volume":"204","author":"Ohmit","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.nano.2015.11.007_bb0245","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1016\/j.vaccine.2006.05.040","article-title":"The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB\/c mice","volume":"24","author":"Cox","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2015.11.007_bb0250","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.virol.2005.06.006","article-title":"Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system","volume":"339","author":"Brett","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.nano.2015.11.007_bb0255","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2009.10.013","article-title":"Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity","volume":"142","author":"Kim","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2015.11.007_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007152","article-title":"Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin","volume":"4","author":"Quan","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2015.11.007_bb0265","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/427813","article-title":"Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants","volume":"191","author":"Karron","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.nano.2015.11.007_bb0270","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1086\/499600","article-title":"The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans","volume":"193","author":"Wright","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.nano.2015.11.007_bb0275","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0264-410X(90)90253-I","article-title":"Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization","volume":"8","author":"Murphy","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2015.11.007_bb0280","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1099\/vir.0.064105-0","article-title":"Characterization of recombinant influenza A virus as a vector expressing respiratory syncytial virus fusion protein epitopes","volume":"95","author":"Zhang","year":"2014","journal-title":"J Gen Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0285","first-page":"1","article-title":"General recommendations on immunization \u2014 recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","year":"2011","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.nano.2015.11.007_bb0290","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2217\/17460794.3.5.445","article-title":"Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination","volume":"3","author":"Castilow","year":"2008","journal-title":"Future Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0295","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease","volume":"196","author":"Polack","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.nano.2015.11.007_bb0300","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1128\/JVI.02541-07","article-title":"Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development","volume":"82","author":"Pribul","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2015.11.007_bb0305","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1086\/593173","article-title":"Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis","volume":"198","author":"Reed","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.nano.2015.11.007_bb0310","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/mi.2013.71","article-title":"Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology","volume":"7","author":"Shirey","year":"2014","journal-title":"Mucosal Immunol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963415002142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963415002142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T06:48:11Z","timestamp":1599893291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963415002142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1549963415002142"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2015.11.007","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2015.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}